Published in Eur Radiol on May 03, 2005
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
In vivo visualization of abdominal malignancies with acoustic radiation force elastography. Phys Med Biol (2007) 1.82
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
In vivo guidance and assessment of liver radio-frequency ablation with acoustic radiation force elastography. Ultrasound Med Biol (2008) 1.13
What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging (2011) 0.99
Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol (2006) 0.96
PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging (2007) 0.90
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol (2007) 0.87
Incorporation of preprocedural PET into CT-guided radiofrequency ablation of hepatic metastases: a nonrigid image registration validation study. J Digit Imaging (2009) 0.86
Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol (2007) 0.86
Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg (2013) 0.83
Radiofrequency ablation: post-ablation assessment using CT perfusion with pharmacological modulation in a rat subcutaneous tumor model. Acad Radiol (2009) 0.82
Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent. Eur Radiol (2006) 0.82
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging (2008) 0.81
Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas. Eur Radiol (2006) 0.80
Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma. Nucl Med Mol Imaging (2012) 0.79
18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade. Eur Radiol (2006) 0.79
The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases. BMC Med Imaging (2014) 0.78
Lack of Anatomical Concordance between Preablation and Postablation CT Images: A Risk Factor Related to Ablation Site Recurrence. Int J Hepatol (2012) 0.77
Differentiation of benign periablational enhancement from residual tumor following radio-frequency ablation using contrast-enhanced ultrasonography in a rat subcutaneous colon cancer model. Ultrasound Med Biol (2012) 0.75
The current role of PET-CT in the characterization of hepatobiliary malignancies. HPB (Oxford) (2009) 0.75
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol (2000) 4.14
Attenuation correction for a combined 3D PET/CT scanner. Med Phys (1998) 3.72
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med (2003) 2.88
Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol (2001) 2.67
Image-guided radiofrequency tumor ablation: challenges and opportunities--part II. J Vasc Interv Radiol (2001) 2.66
Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer (2000) 2.59
Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology (2003) 2.53
Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol (2000) 2.51
Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. J Vasc Interv Radiol (2001) 2.41
Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol (1998) 2.23
Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol (2001) 2.03
Radiofrequency ablation of malignant liver tumors. Oncologist (2001) 1.97
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol (2000) 1.95
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Surgical treatment of liver metastases in patients with colorectal cancer. Cancer (1993) 1.67
Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg (1998) 1.63
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology (1993) 1.53
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology (2002) 1.44
Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology (2001) 1.43
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging (2003) 1.31
Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist (2001) 1.31
Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol (2004) 1.28
Value of CT volume imaging for optimal placement of radiofrequency ablation probes in liver lesions. J Vasc Interv Radiol (2002) 1.11
Radio-frequency tissue ablation of the liver: in vivo and ex vivo experiments with four different systems. Eur Radiol (2003) 1.11
Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results. Abdom Imaging (2001) 1.10
FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med (2003) 1.03
Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med (2002) 1.03
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology (2004) 1.01
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging (2002) 1.00
Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol (2002) 0.99
[F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol (2003) 0.97
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol (2002) 0.88
Interpretation of CT and MRI after radiofrequency ablation of hepatic malignancies. AJR Am J Roentgenol (2003) 0.86
Influence of detector collimation on SNR in four different MDCT scanners using a reconstructed slice thickness of 5 mm. Eur Radiol (2004) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke (2014) 2.71
A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke (2007) 2.70
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging (2009) 2.67
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation (2010) 2.14
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis (2006) 1.91
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer (2005) 1.73
Treatment of wide-necked intracranial aneurysms with a self-expanding stent system: initial clinical experience. AJNR Am J Neuroradiol (2003) 1.62
Double-stent method: therapeutic alternative for small wide-necked aneurysms. Technical note. J Neurosurg (2004) 1.62
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol (2007) 1.59
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57
Evaluation of living liver donors with an all-inclusive 3D multi-detector row CT protocol. Radiology (2006) 1.55
Imaging of patients with hippocampal sclerosis at 7 Tesla: initial results. Acad Radiol (2009) 1.54
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med (2012) 1.53
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
High-profile flow diverter (silk) implantation in the basilar artery: efficacy in the treatment of aneurysms and the role of the perforators. Stroke (2010) 1.51
¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging (2012) 1.50
Short term effects of magnetic resonance imaging on excitability of the motor cortex at 1.5T and 7T. Acad Radiol (2009) 1.50
European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis (2013) 1.50
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48
Shortcomings and promises of recent carotid-stenting trials. Lancet Neurol (2007) 1.44
Segmentation of PET volumes by iterative image thresholding. J Nucl Med (2007) 1.43
MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging (2008) 1.42
Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging (2009) 1.41
Avoidance of proximal endoleak using a hybrid stent graft in arch replacement and descending aorta stenting. Ann Thorac Surg (2009) 1.41
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging (2003) 1.31
Interventional magnetic resonance angiography with no strings attached: wireless active catheter visualization. Magn Reson Med (2005) 1.30
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med (2008) 1.28
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27
Stents for intracranial wide-necked aneurysms: more than mechanical protection. Neuroradiology (2008) 1.22
Timing of conditioned eyeblink responses is impaired in cerebellar patients. J Neurosci (2005) 1.22
Inductively coupled stent antennas in MRI. Magn Reson Med (2002) 1.20
Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol (2013) 1.19
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol (2003) 1.17
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging (2010) 1.17
Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res (2006) 1.14
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13
Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology (2010) 1.12
Value of CT volume imaging for optimal placement of radiofrequency ablation probes in liver lesions. J Vasc Interv Radiol (2002) 1.11
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab (2002) 1.10
Three-dimensional delayed gadolinium-enhanced magnetic resonance imaging of hip joint cartilage at 3T: a prospective controlled study. Eur J Radiol (2012) 1.09
Evaluation of brain injury after coronary artery bypass grafting. A prospective study using neuropsychological assessment and diffusion-weighted magnetic resonance imaging. Eur J Cardiothorac Surg (2004) 1.09
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg (2010) 1.09
Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. Eur Radiol (2009) 1.08
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med (2012) 1.08
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging (2007) 1.08
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab (2004) 1.08
Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol (2008) 1.08
Brain tissue water uptake after middle cerebral artery occlusion assessed with CT. J Neuroimaging (2004) 1.08
Cross-modal plasticity in deaf subjects dependent on the extent of hearing loss. Brain Res Cogn Brain Res (2005) 1.07
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. Mol Imaging Biol (2004) 1.07
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Prevalence of pulmonary hypertension associated with severe acute respiratory distress syndrome: predictive value of computed tomography. Intensive Care Med (2006) 1.06
Endovascular treatment of unruptured intracranial aneurysms. AJNR Am J Neuroradiol (2002) 1.05
Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging (2012) 1.05
Dual-energy-CT of hypervascular liver lesions in patients with HCC: investigation of image quality and sensitivity. Eur Radiol (2010) 1.05
Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol (2013) 1.05